ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 49

Chondrocyte-Specific Bone Morphogenetic Protein-2 Overexpression Results In Severe Aggravation Of Osteophyte Formation In Experimental Osteoarthritis Without Altering Cartilage Damage In Young Mice

Esmeralda N. Blaney Davidson1, Elly L. Vitters2, Miranda B. Bennink3, Fons AJ Loo2, Wim B. van den Berg3 and Peter M. van der Kraan2, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, cartilage, growth factors, osteoarthritis and osteophytosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: In murine osteoarthritis (OA) models chondrocytes surrounding lesions express elevated levels of Bone Morphogenetic Protein-2 (BMP2). This growth factor is well known for its ECM inducing qualities and capability to induce new cartilage and bone. The functional consequence of these elevated BMP2 levels near OA lesions is unclear. We made a collagen type II dependent, doxycycline-inducible BMP2 transgenic mouse to investigate the consequence of elevated chondrocyte-specific BMP2 on experimental OA (DMM-model).

Methods: We cloned a lentivirus with BMP2 controlled by minCMV promoter coupled to a tet responsive element (Lv-TRE-BMP2).We crossed a Col2-cre with a floxed rtTA mouse and transfected homozygote embryo’s with Lv-TRE-BMP2 to gain a mouse expressing collagen type 2 dependent BMP2 solely in chondrocytes only upon doxycycline (dox) exposure (Col2-rtTA-TRE-BMP2). Experimental OA was induced (DMM model) in Col2-rtTA-TRE-BMP2 mice with or without dox exposure in food starting one week before DMM, lasting until the end of the experiment (8 weeks after DMM). We isolated knee joints for histology. Left knee joints served as non-OA controls.

Results: Mice with DMM alone showed osteophyte formation predominantly on the medial side of the joint originating from the periost near the femoral-tibial joint and extruding from the medial meniscus. Upon chondrocyte-specific BMP2 exposure, DMM-induced osteophyte formation aggravated severely resulting in outsized osteophytes, enthesophytes on the enthesis of the medial collateral ligament, new bone formation within the collateral ligament near the extruded meniscus and osteophyte formation originating from the femoral growth plate, predominantly but not exclusively on the medial side of the joint. There were no significant differences in non-OA knee joints comparing dox versus non-dox treated transgenics. In contrast, dox treatment resulted in large osteophytes in thoracic or cervical area of the spine. Strikingly, despite apparent changes in knee joint morphology due to large osteophytes there was no detectible difference, with regard to structural damage and Safranin O staining intensity, in cartilage damage when comparing DMM with or without dox exposure.

Conclusion: Elevated BMP2 levels in chondrocytes did not induce structural changes in articular cartilage of young mice. Moreover, unchallenged dox treated joints had no structural alterations in cartilage. In DMM, BMP2 overexpression greatly enhanced de novo cartilage formation, eventually turning into bone (osteophytes), which was not seen in non-OA knee joints with BMP2. We postulate that newly-induced chondrocytes produce high BMP2 levels in dox-treated transgenics, that boost outgrowth of these structures. In spine however, osteophytes developed in dox-treated transgenics without additional triggers. This could rely on chondrocyte precursor subpopulation that is stimulated to undergo chondrogenesis under control of BMP2 alone.
Our data show that chondrocyte-specific elevation of BMP2 levels does not alter the course of cartilage damage in an OA model in young mice but results in severe aggravation of osteophyte formation.


Disclosure:

E. N. Blaney Davidson,
None;

E. L. Vitters,
None;

M. B. Bennink,
None;

F. A. Loo,
None;

W. B. van den Berg,
None;

P. M. van der Kraan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chondrocyte-specific-bone-morphogenetic-protein-2-overexpression-results-in-severe-aggravation-of-osteophyte-formation-in-experimental-osteoarthritis-without-altering-cartilage-damage-in-young-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology